诺泰生物：醋酸阿托西班注射液获药品注册证书

Core Viewpoint - The approval of Acetate Atosiban Injection by the National Medical Products Administration represents a significant step for the company in expanding its product offerings in the assisted reproductive medicine sector, enhancing its competitive position in the market [1] Group 1: Product Approval - The company has received the drug registration certificate for Acetate Atosiban Injection, which is available in two specifications: 0.9ml containing 6.75mg and 5ml containing 37.5mg [1] - The effective period of the drug is 18 months, with the approval number valid until 2030 [1] Group 2: Market Implications - Acetate Atosiban is a selective oxytocin receptor antagonist, indicated for pregnant women with signs of preterm labor [1] - The approval is expected to enhance the company's competitiveness in the assisted reproductive drug field, although the sales of the product may be influenced by multiple factors, leading to uncertainty regarding its short-term impact on performance [1]